Analyst Group: Analyst Group Comments on Pila Pharma’s Confirmation That Low Exposure of XEN-D0501 Plausibly Resulted in the Absence of Effects in Preclinical Obesity Studies

PILAPressmeddelande17.04.2026 klo 10.05

Pila Pharma AB (”Pila Pharma” or ”the Company”) announced on 16 April 2026 that the systemic exposure of XEN-D0501 in the obese rats in the Company’s preclinical studies was very low, and that this plausibly explains the lack of effect on body weight reported in January 2026. The Company states that at these low exposure levels it is not possible to draw any conclusions about the effect of XEN-D0501 on body weight or other parameters. Pila Pharma announces that it intends to proceed as planned towards a clinical trial in obesity using the Company’s current tablet formulation, for which good exposure has already been demonstrated in humans, and that the study is expected to evaluate higher doses and longer treatment duration than applied in the preclinical studies.

Exposure data confirmed: the absence of weight loss effects reported in January 2026 was plausibly attributable to insufficient drug exposure resulting from the change in formulation, not to lack of efficacy. This reduces the uncertainty surrounding the development plan.
The Company characterises the outcome as a false negative result and plans to continue clinical development in obesity, which is now assessed to proceed at lower risk than would have been the case had exposure in the obese rats been adequate, something that we argue is a positive from a valuation perspective.
The planned clinical study in obesity is expected to evaluate higher doses and longer treatment duration using a formulation in which good human exposure has already been demonstrated, thereby reducing exposure risk.
Pila Pharma is assessed to be funded to conduct a clinical Phase Ib/IIa study in obesity.

In summary, today’s announcement confirms that the preclinical results presented in January 2026 constituted a false negative outcome, and that the efficacy potential of XEN-D0501 in obesity has not yet been tested under adequate exposure conditions. Analyst Group assesses the news as removing the uncertainty surrounding the obesity programme and as enabling continued clinical development at lower risk than would have been the case had the outcome been the opposite. The clinical study is expected to be conducted using the existing tablet formulation for which good human exposure is already documented, with the study planned to evaluate higher doses and longer treatment duration.

Read Analyst Group’s comment here

About Analyst Group: One of Sweden's leading equity research boutiques with focus on small and medium-sized listed companies.
Read more about Analyst Group

This is a press release from Analyst Group regarding the publication of a comment on Pila Pharma. Readers may assume that Analyst Group has received compensation for making the comment. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.